Phase II Clinical Trial of Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
Summary
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives.
Why it matters
This trial represents an important advancement in neurotechnology for treating Primary Progressive Aphasia. If successful, the device-based intervention could provide a new therapeutic option for patients who have not responded adequately to conventional treatments or therapies. The study results may inform future regulatory approval pathways and establish clinical precedent that could benefit broader patient populations with similar conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial